Unicycive Therapeutics, Inc.
UNCY · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $78,765 | $58,681 | $67,171 | $53,186 |
| - Cash | $42,695 | $22,327 | $19,769 | $26,142 |
| + Debt | $265 | $476 | $694 | $773 |
| Enterprise Value | $36,335 | $36,830 | $48,096 | $27,817 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$5,848 | -$6,296 | $720 | -$9,254 |
| % Margin | – | – | – | – |
| Net Income | -$6,011 | -$6,447 | $570 | -$21,525 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.33 | -0.52 | -0.502 | -2 |
| % Growth | 36.5% | -3.6% | 74.9% | – |
| Operating Cash Flow | -$5,962 | -$8,420 | -$8,903 | -$6,548 |
| Capital Expenditures | -$2 | -$6 | -$16 | -$22 |
| Free Cash Flow | -$5,964 | -$8,426 | -$8,919 | -$6,570 |